Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02053493 · ClinicalTrials.gov registry record · Phase 2

Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction

A Phase 2 study, sponsored by Adrian Hernandez.

Completed
Registry status
Phase 2
Development phase
110
Enrollment target

NCT02053493: Completed Phase 2 study, sponsored by Adrian Hernandez.

NCT02053493 is a Phase 2 study that has completed, run by Adrian Hernandez. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02053493, a Phase 2 study, has completed, sponsored by Adrian Hernandez.

COMPLETED
Registry status
Phase 2
Development phase
110 participants
Enrollment target

Study Summary

A randomized, double-blinded, placebo-controlled crossover study to assess effect of isosorbide mononitrate with dose up-titration on activity tolerance as assessed by (hip-worn, tri-axial) accelerometry.

Primary Outcome

To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement.

Interventions

  • DRUG Placebo
  • DRUG Isosorbide Mononitrate

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2014-04
Est. Completion 2015-03
Phase Phase 2
Adrian Hernandez

7 total trials

What the finished NCT02053493 record still lists

NCT02053493 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02053493 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02053493 about?

NCT02053493 is a clinical study titled "Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction". A randomized, double-blinded, placebo-controlled crossover study to assess effect of isosorbide mononitrate with dose up-titration on activity tolerance as assessed by (hip-worn, tri-axial) accelerometry.

What is the current status of trial NCT02053493?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2014-04. Estimated completion is 2015-03.

What interventions are being tested in trial NCT02053493?

The interventions under investigation include: Placebo (DRUG), Isosorbide Mononitrate (DRUG).

Who is sponsoring clinical trial NCT02053493?

This trial is sponsored by Adrian Hernandez, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02053493's enrollment target sits among peer trials

110 632nd of 2000 higher than 1,361 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02053493, the US trial registry maintained by the National Library of Medicine. NCT02053493 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.